ArticlePharmacoEconomics2025

Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand.

Richard J Milne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.